PTAB Declines to Institute IPR Proceedings Against Three Biogen TYSABRI® Formulation Patents, PTAB Litigation Blog
Visit the Jones Day PTAB Litigation Blog.
On October 17, 2016, the PTAB declined the requests of Swiss Pharma International AG ("Swiss Pharma") in cases IPR2016-00912, IPR2016-00915, and IPR2016-00916 to institute inter partes reviews ("IPRs") of three patents owned by Biogen Idec MA, Inc. ("Biogen"). The patents-at-issue—U.S. Patent 8,815,236 B2 ("the ’236 patent"), U.S. Patent 8,349,321 B2 ("the ’321 patent"), and U.S. Patent 8,900,577 B2 ("the ’577 patent")—relate to certain stable, high concentration formulations of the humanized monoclonal antibody natalizumab. Natalizumab is commercialized by Biogen as TYSABRI® for use in treating multiple sclerosis.
Read the full article at www.ptablitigationblog.com.
Insights by Jones Day should not be construed as legal advice on any specific facts or circumstances. The contents are intended for general information purposes only and may not be quoted or referred to in any other publication or proceeding without the prior written consent of the Firm, to be given or withheld at our discretion. To request permission to reprint or reuse any of our Insights, please use our “Contact Us” form, which can be found on our website at www.jonesday.com. This Insight is not intended to create, and neither publication nor receipt of it constitutes, an attorney-client relationship. The views set forth herein are the personal views of the authors and do not necessarily reflect those of the Firm.
